此次罚款总计3255万元，根据处罚决定，公司被责令改正、给予警告，并处以900万元罚款；时任董事长李卫伟被处 以1400万元罚款；时任副董事长曾开天被处以350万元罚款。 公开财务数据显示，2022年至2024年，三七互娱累计现金分红57.78亿元；2025年前三季度，公司累计分红13.86亿 元。按持股比例计算，2025年第三季度，李卫伟个人分红约6750万元，曾开天约5146万元。 2024年年度报告披露，李卫伟年薪为1380.09万元，较2023年增长61.8%；曾开天年薪为1447.01万元，较2023年增长 551万元。其他核心高管年薪均超过1000万元。 2025年前三季度，三七互娱营业收入同比下降6.59%，净利润同比增长23.57%。市场对此次处罚的解读存在不同观 点，部分分析认为处罚已消除退市风险。同时，公司产品线更新问题引发关注，2025年第三季度多款新游戏用户留 存率及流水表现未达预期。 三七互娱多项关联交易未披露等违法行为被证监会处罚，责令改正，给予警告并处罚款 12月5日，三七互娱发布公告称，公司及相关人员李卫伟、曾开天、胡宇航、杨军、叶威、吴卫红已收到中国证券监 督管理委员会（证监 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 斑马消费 范建 一边面临高达17亿元的诉讼，另一边被证监会立案调查。贵州百灵实控人、贵州前首富姜伟的这个冬天，寒冷异常。 正如他自己所感受的那样——似乎所有的矛头开始转向他个人。 创业30年，他一手打造出"苗药第一股"贵州百灵，一度在资本市场高歌猛进。而最近几年，上市公司和他频陷非议，已影响投资者们的信心。 作为公司创始人，姜伟和贵州百灵，一损俱损、一荣俱荣。如果能顺利度过这个多事之秋，姜伟或许应该重新考虑调整自己的投资版图。 矛头开始指向个人 最近两三年，贵州百灵（002424.SZ）的投资者们始终战战兢兢，不知道什么时候，就会有一个利空的消息降临。 这不，坏消息又来了。 12月3日盘后，公司披露公告，实控人姜伟已于近日收到证监会的《立案告知书》，他因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，被立案 调查。 上市公司表示，本次立案是对姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对公司及子公司生产经营活动产生影响。 为安抚内外，姜伟通过贵州百灵官方公众号，发表了一篇公开信。他在信中表示，自己将全力配合证监会的调查，"实践中，经调查确无问题的 ...

知名医药企业贵州百灵（002424.SZ）的实际控制人涉嫌内幕交易，被中国证监会立案调查。 12月3日晚，贵州百灵发布公告称，当日，公司收到实际控制人姜伟通知，其因涉嫌内幕交易、信息披 露违法、违反限制性规定转让股票等，被中国证监会立案调查。 贵州百灵公告称，证监会本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活 动无关。 近年来，贵州百灵及相关负责人频频违规，频频被采取监管措施处罚。2024年8月，公司因内部控制存 在重大缺陷等被贵州证监局责令改正。2024年11月，公司因涉嫌信息披露违法违规被证监会立案调查。 贵州百灵的经营业绩也不理想。2023年，公司曾亏损4.15亿元；2025年前三季度，公司实现的营业收 入、归母净利润分别约为21亿元、0.57亿元，同比均下降。 贵州百灵的销售费用偏高。2024年，公司销售费用18.54亿元，占营业收入的48.47%。2020年至2024 年，贵州百灵投入的销售费用累计超过81亿元，吞噬了利润。 2020年至2024年，贵州百灵连续5年未派发现金红利。 频频违法违规实控人被立案 贵州百灵的实际控制人姜伟被证监会立案调查了。 长江商报消息 ●长江商 ...

此外，姜伟同样提到，最近几年，贵州百灵和其个人非议不断。"2024年上半年，公司股票被ST处理；2025年公司完 成摘帽，各方面发展重回正轨，我作为公司控股股东却又遭到华创证券无理巨额起诉；今天，我个人又受到中国证监 会的立案调查。这一切都让我有一个强烈的感觉：似乎矛头开始转向了我个人。"。 全员信中提到，目前，贵州百灵一切运营井然有序，发展态势稳健。 近日，贵州百灵企业集团制药股份有限公司（以下简称"公司"）收到公司实际控制人姜伟的通知，其于近日收到中国 证券监督管理委员会（以下简称"中国证监会"）下发的《立案告知书》（编号：证监立案字03720252005号）。 按照该告知书，姜伟因涉嫌内幕交易、信息披露违法、违反限制性规定转让股票，根据《中华人民共和国证券法》 《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其进行立案。 公告表示，本次立案系对公司实际控制人姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及 子公司生产经营活动产生影响。立案调查期间，姜伟将积极配合中国证监会的立案调查工作。公司将持续关注上述事 项的进展情况，并严格按照相关法律法规及监管要求及时履行信息披露义务。 ...

贵州百灵（002424）（002424.SZ）实控人姜伟涉嫌内幕交易等问题被证监会立案，姜伟当晚通过公司官微发布公开信回应称，"实践中，经调查确无问题的 情况亦非少数。请各位同事保持冷静，不必过度担忧。" 12月3日晚，贵州百灵发布公告称，公司收到实控人姜伟的通知，其于近日收到中国证监会下发的《立案告知书》。按照该告知书，姜伟因涉嫌内幕交易、 信息披露违法、违反限制性规定转让股票，根据相关法律法规，证监会决定对其进行立案。 苗药企业贵州百灵近年来可谓风雨飘摇，从上市公司到实控人姜伟个人"麻烦"不断。 2023年度年报，贵州百灵被天健会计师事务所（特殊普通合伙）出具了否定意见的《内部控制审计报告》，涉及销售费用计提滞后、财务报告内部控制失效 等问题，公司股票于2024年5月6日被实施其他风险警示，证券简称变更为"ST百灵"。2024年11月，贵州百灵收到中国证监会的《立案告知书》，公司因涉 嫌信息披露违法违规被中国证监会立案调查。 立案调查事项尚未完结之际，2025年4月，贵州百灵2024年度财务报表被审计机构出具了带强调事项段的保留意见的审计报告。保留意见所涉事项为年审会 计师无法就某种苗药产品主要原材料可变 ...

Core Viewpoint - Guizhou BaiLing Pharmaceutical Group Co., Ltd. announced that its actual controller, Jiang Wei, is under investigation by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, which is unrelated to the company's daily operations and will not affect its business activities [2][18]. Group 1: Investigation and Company Response - Jiang Wei, the chairman of Guizhou BaiLing, is being investigated for insider trading and related violations, and he will cooperate with the CSRC during the investigation [2][20]. - The company reassured stakeholders that the investigation pertains solely to Jiang Wei and will not impact the company's operations or management [2][18]. - Jiang Wei sent a letter to employees urging them to remain focused on their work and not to worry excessively about the situation, emphasizing the importance of maintaining productivity [20][19]. Group 2: Financial and Legal Context - Jiang Wei is involved in a legal dispute with Huachuang Securities regarding a financial rescue plan and stock pledge disputes, with the total amount in question reaching 1.761 billion yuan, including principal and related fees [7][24]. - Since 2018, Jiang Wei has faced financial difficulties due to heavy debt burdens and declining stock prices, leading to a significant increase in stock pledge ratios [8][25]. - As of the third quarter, Jiang Wei held 245 million shares of Guizhou BaiLing, representing a 17.55% stake, all of which are pledged [12][29]. Group 3: Company Financial Performance - Guizhou BaiLing reported a third-quarter revenue of 640 million yuan, a year-on-year increase of 1.11%, while the net profit attributable to shareholders was 4.98 million yuan, up 559.90% [15][32]. - For the first three quarters, the company's revenue was 2.102 billion yuan, a decrease of 24.28%, with a net profit of 56.81 million yuan, down 35.60% [15][32]. - The company's stock price closed at 5.57 yuan on December 3, reflecting a year-to-date increase of over 44% [16][33].

Group 1 - Guizhou BaiLing's actual controller Jiang Wei has been investigated by the China Securities Regulatory Commission (CSRC) for insider trading and information disclosure violations, indicating a focus on regulatory enforcement against key individuals [1] - The investigation may exacerbate operational uncertainties for Guizhou BaiLing, which has faced performance pressures in recent years, raising concerns about corporate governance and information disclosure risks [1] Group 2 - Jianyou Co., Ltd. has received ANDA approval from the FDA for its propofol emulsion injection, marking a significant step in the company's internationalization of its formulations [2] - The product, commonly used for sedation during surgeries, has substantial market potential in the U.S., which is expected to contribute to revenue growth for Jianyou [2] Group 3 - Shenzhen Xinlitai Pharmaceutical Co., Ltd. has been granted clinical trial approval for its innovative small molecule drug SAL0140, aimed at treating chronic kidney disease (CKD) [3] - SAL0140, an aldosterone synthase inhibitor, targets multiple significant chronic disease areas, including uncontrolled hypertension and CKD, presenting considerable market potential for the company [3] Group 4 - Junshi Biosciences reported a decrease in the shareholding percentage of Greenland Financial Investment Group and its affiliates from 5.0051% to 4.7129% due to share lending, falling below the 5% disclosure threshold [4] - This change is primarily a technical operation rather than an active reduction in holdings, but the market will need to monitor the future actions of these shareholders [4] Group 5 - Sichuang Medical Technology has elected Wei Naixu as the new chairman following the resignation of Xu Yiran, who stepped down to facilitate governance structure optimization [5] - Xu Yiran will remain on the board, indicating that the adjustment aims to clarify responsibilities and strengthen governance rather than signaling a crisis [5]

【导读】贵州百灵实控人姜伟被立案，涉嫌内幕交易、信披违法等 中国基金报记者 晨曦 又有上市公司实控人被立案！ 12月3日晚间，贵州百灵发布公告称，公司实控人姜伟被证监会立案，涉嫌内幕交易、信息披露违法、违反限制性规定转让股票。 此前， 贵州百灵因涉嫌信息披露违法违规，于2024年11月被证监会立案调查，调查结果尚未公布。 贵州百灵实控人姜伟被立案 12月3日晚间，贵州百灵公告称，公司实际控制人姜伟于近日收到证监会下发的《立案告知书》。按照该告知书，姜伟因涉嫌内幕交易、信 息披露违法、违反限制性规定转让股票，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，证监会决定对其进 行立案。 对此，贵州百灵表示，该次立案系对姜伟个人的调查，与公司日常经营管理和业务活动无关，不会对上市公司及子公司生产经营活动产生 影响。立案调查期间，姜伟将积极配合中国证监会的立案调查工作。公司将持续关注上述事项的进展情况，并严格按照相关法律法规及监 管要求及时履行信息披露义务。 公开信息显示，姜伟出生于1961年，1982年毕业于贵阳中医学院药学系，大学文化，高级工程师，现任贵州百灵董事长。姜伟于1996年 主导安顺制 ...

Core Viewpoint - The actual controller of Guizhou Bailing, Jiang Wei, has been placed under investigation by the China Securities Regulatory Commission (CSRC) for insider trading, information disclosure violations, and illegal stock transfers [4][17]. Group 1: Investigation Details - Jiang Wei received a notice of investigation from the CSRC, which states that he is suspected of insider trading and violating information disclosure regulations [4][17]. - Guizhou Bailing clarified that the investigation pertains to Jiang Wei personally and will not affect the company's daily operations or business activities [4][17]. - The company will continue to monitor the situation and fulfill its information disclosure obligations as required by law [4][18]. Group 2: Background on Jiang Wei - Jiang Wei, born in 1961, graduated from Guizhou University of Traditional Chinese Medicine in 1982 and is currently the chairman of Guizhou Bailing [4][18]. - He has been instrumental in the company's development, leading the launch of several well-known traditional medicine products and overseeing its listing on the Shenzhen Stock Exchange in 2010 [4][18]. Group 3: Regulatory History - Guizhou Bailing has faced multiple regulatory actions in recent years, including corrective measures and warnings from the Guizhou Securities Regulatory Bureau due to issues with financial disclosures and internal controls [5][18]. - The company was previously investigated for information disclosure violations in November 2024, with the results of that investigation still pending [6][19]. Group 4: Legal Disputes - Jiang Wei is involved in a legal dispute with Huachuang Securities regarding a rescue plan and stock pledge disputes, with claims amounting to 1.4 billion yuan and 361 million yuan respectively [21][22]. - The disputes arose from allegations that Jiang Wei failed to fulfill obligations related to stock repurchase and repayment, leading to litigation [21][22]. - As of September 2025, Jiang Wei holds 17.55% of Guizhou Bailing's shares, while Huachuang Securities holds 11.54% through asset management plans [22]. Group 5: Financial Performance - For the first three quarters of 2025, Guizhou Bailing reported revenues of 2.102 billion yuan, a year-on-year decrease of 24.28%, and a net profit attributable to shareholders of 57 million yuan, down 35.6% year-on-year [23]. - As of December 3, 2025, the company's stock price was 5.57 yuan per share, with a total market capitalization of 7.785 billion yuan [24].

贵州百灵（002424）(002424.SZ)发布公告，公司收到公司实际控制人姜伟先生的通知，其于近日收到 中国证券监督管理委员会(以下简称"中国证监会")下发的《立案告知书》(编号：证监立案字 03720252005号)。按照该告知书，姜伟先生因涉嫌内幕交易、信息披露违法、违反限制性规定转让股 票，根据《中华人民共和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对其 进行立案。 ...